Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
18.20
-0.14
(
-0.76% )
|
18.20
|
1,600 |
18.21
|
100 |
Analysis date: 29.08.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 12.08.2025.
Interest
Weak
Weak
Two stars since 26.08.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 12.08.2025 at a price of 18.80.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 26.08.2025.
4wk Rel Perf
13.57%
13.57%
The four-week dividend-adjusted overperformance versus SP500 is 13.57%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.22%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 6.81%.
Mkt Cap in $bn
1.78
1.78
With a market capitalization <$2bn, SAREPTA THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
0.61
0.61
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
13.45
13.45
The estimated PE is for the year 2028.
LT Growth
8.24%
8.24%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
19
19
Over the last seven weeks, an average of 19 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
75
75
For 1% of index variation, the stock varies on average by 0.75%.
Correlation
0.18
0.18
Stock movements are totally independent of index variations.
Value at Risk
12.17
12.17
The value at risk is estimated at USD 12.17. The risk is therefore 66.87%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013